Advertisement
Advertisement
U.S. markets open in 5 hours 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Fresenius Medical Care AG & Co. KGaA (FME.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
47.60-0.41 (-0.85%)
As of 09:15AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close48.01
Open47.27
Bid47.56 x 38700
Ask47.65 x 105300
Day's Range47.35 - 47.75
52 Week Range43.53 - 71.14
Volume40,631
Avg. Volume552,184
Market Cap13.948B
Beta (5Y Monthly)0.94
PE Ratio (TTM)15.89
EPS (TTM)3.00
Earnings DateAug 02, 2022
Forward Dividend & Yield1.35 (2.73%)
Ex-Dividend DateMay 13, 2022
1y Target Est64.66
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for FME.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      UPDATE 1-U.S. Supreme Court rules against DaVita over dialysis coverage

      The U.S. Supreme Court on Tuesday rejected dialysis provider DaVita Inc's claims that an Ohio hospital's employee health plan discriminates against patients with end-stage kidney disease by reimbursing them at low rates in hopes they would switch to Medicare. In a 7-2 decision https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrjaqorve/06212022davita.pdf authored by conservative Justice Brett Kavanaugh, the court ruled that Marietta Memorial Hospital's employee health plan did not violate federal law by limiting benefits for outpatient dialysis because it did so without regard to whether patients had end-stage renal disease.

    • Zacks

      Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

      Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

    • Business Wire

      Fresenius Medical Care Celebrates Diversity and Unity of a Global Nurse Workforce

      HONG KONG, May 12, 2022--Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced its global ‘United in Care’ campaign that celebrates the diversity, unity and positive impact of its nurses and clinical teams across Asia Pacific, Europe, the Middle East and Africa, North America and Latin America.

    Advertisement
    Advertisement